A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

Exclusion Criteria

• •PD:
• •1. Late-stage PD diagnosis (i.e., Hoehn \& Yahr Stage 5) at Screening Visit
• •2. Symptomatic or atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).
• •3. Current or active clinically significant neurological disorder other than PD (in the opinion of the Investigator).
• •4. Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
• •5. History of drug and/or alcohol abuse within the past year prior to Screening Visit.
• •6. Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
• •7. Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
• •Prodromal PD:
• •1. Clinical diagnosis of PD, other parkinsonism, or dementia.
• •2. Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
• •3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
• •4. Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
• •5. History of drug and/or alcohol abuse within the past year prior to Screening Visit.
• •6. Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
• •7. Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
• •Age \& Sex Matched Healthy Control:
• •1. First degree relative with PD (i.e., biologic parent, sibling, child).
• •2. Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
• •3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
• •4. Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
• •5. History of drug and/or alcohol abuse within the past year prior to Screening Visit.
• •6. Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
• •7. Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation